The first poster presented at the AAO meeting, titled "Dosing Profile of XEOMIN (incobotulinumtoxinA) During Long-Term, Open-Label Treatment of Benign Essential Blepharospasm," evaluated the repeat-dosing profile of XEOMIN for up to 48 weeks, including the inter-injection interval, during an open-label extension (OLEX) of the Phase III randomized, double-blind trial that evaluated XEOMIN versus placebo. Although the injection frequency varied during the OLEX and many participants received injections at less than 12-week intervals, the investigator-determined dosing profile of XEOMIN remained similar to the initial single-treatment study, which was based on prior treatment with Botox®. [PO440, Oct. 24, 2011, 2 – 3:30 p.m. ET, Hall A1]
The second poster presented at the AAO meeting, titled "Adverse Event (AE) Profile of XEOMIN (incobotulinumtoxinA) in the Benign Essential Blepharospasm (BEB) Clinical Trials Program," assessed the AE profile of XEOMIN across two single-treatment trials (one versus placebo and one versus Botox®), as well as one repeat-treatment study (OLEX of the Phase III placebo-controlled study). [PO441, Oct. 24, 2011, 2 – 3:30 p.m. ET, Hall A1]
"Our community is always interested in learning more about XEOMIN and we are pleased to see these important data published in a prestigious journal and presented at the American Academy of Ophthalmology meeting. Merz has taken a strong interest in the blepharospasm community and the Company's commitment to educational programming is welcomed by the Benign Essential Blepharospasm Research Foundation," said Mary Lou (Koster) Thompson, BEBRF President.
About The Phase III Placebo-controlled Study and OLEXThe Phase III, randomized, placebo-controlled, double-blind study published in the journal Movement Disorders evaluated blepharospasm patients
|SOURCE Merz Pharmaceuticals|
Copyright©2010 PR Newswire.
All rights reserved